After Roth Capital and Cowen & Co. assigned a Buy rating to Lion Biotechnologies Inc in the last month, the company received another Buy, this time from FBR Capital. Analyst Edward White reiterated a Buy rating on Lion Biotechnologies Inc (NASDAQ: LBIO) today. The company’s shares opened today at $6.
According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -5.1% and a 41.8% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and RXi Pharmaceuticals Corp.
Currently, the analyst consensus on Lion Biotechnologies Inc is Strong Buy and the average price target is $14, representing a 133.3% upside.
In a report released yesterday, Jefferies also reiterated a Buy rating on the stock with a $11 price target.
The company has a one year high of $9.58 and a one year low of $4.94. Currently, Lion Biotechnologies Inc has an average volume of 257.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lion Biotechnologies, Inc. operates as a biotechnology company which focuses on the development and commercialization of novel cancer immunotherapy. It products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The company services include adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma. Lion Biotechnologies was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.